Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
11%(1 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_3
1
8%
Ph early_phase_1
1
8%
Ph phase_1
11
85%

Phase Distribution

12

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
11(84.6%)
Phase 3Large-scale testing
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

9 of 12 finished

Non-Completion Rate

25.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(9)
Terminated(3)
Other(1)

Detailed Status

Completed9
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
81.8%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (7.7%)
Phase 111 (84.6%)
Phase 31 (7.7%)

Trials by Status

unknown18%
withdrawn18%
completed969%
terminated215%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_3

Phase III Study on HMPL-523 for Treatment of ITP

NCT05029635
terminatedphase_1

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

NCT03779113
completedphase_1

Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets

NCT07348133
withdrawnphase_1

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

NCT06291415
completedphase_1

Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects

NCT05781906
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05029635Phase 3

Phase III Study on HMPL-523 for Treatment of ITP

Completed
NCT03779113Phase 1

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Terminated
NCT07348133Phase 1

Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets

Completed
NCT06291415Phase 1

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Withdrawn
NCT05781906Phase 1

Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects

Completed
NCT03951623Phase 1

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

Completed
NCT02857998Phase 1

A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

Completed
NCT05318820Early Phase 1

A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers

Completed
NCT05720767Phase 1

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

Completed
NCT05571787Phase 1

HMPL-523 Food Effect and Proton Pump Inhibitor Study

Completed
NCT02503033Phase 1

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

Unknown
NCT03483948Phase 1

Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

Terminated
NCT02105129Phase 1

A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13